Zacks Investment Research cut shares of ABLYNX (OTCMKTS:ABLYF) from a buy rating to a hold rating in a report published on Friday morning.

According to Zacks, “Ablynx NV is a biopharmaceutical company which engaged in the development of Nanobodies (R) proprietary therapeutic proteins based on single-domain antibody fragments. The company also discovers and develops therapeutic for inflammation, haematology, immuno-oncology, oncology and respiratory disease. Ablynx NV is headquartered in Ghent, Belgium. “

Separately, Bank of America started coverage on shares of ABLYNX in a research report on Friday, November 10th. They issued a buy rating and a $26.00 price objective on the stock.

ABLYNX (OTCMKTS:ABLYF) remained flat at $$38.48 during trading hours on Friday. ABLYNX has a one year low of $11.10 and a one year high of $50.00.

COPYRIGHT VIOLATION NOTICE: “ABLYNX (ABLYF) Downgraded by Zacks Investment Research to “Hold”” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2018/01/13/ablynx-ablyf-downgraded-by-zacks-investment-research-to-hold.html.

About ABLYNX

Ablynx NV, a biopharmaceutical company, develops Nanobodies that is a proprietary therapeutic protein based on single-domain antibody fragments for the treatment of various diseases. The company develops products in various therapeutic areas, such as inflammation, hematology, immuno-oncology, oncology, and respiratory diseases.

Get a free copy of the Zacks research report on ABLYNX (ABLYF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ABLYNX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABLYNX and related companies with MarketBeat.com's FREE daily email newsletter.